Valeria F.
- Country
- Italy
- Department
- UO Ematologia - TMO
Research Overview
- A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
- Phase 3 Randomized Trial of Teclistamab and Talquetamab Combinations Versus Standard Regimen in Newly Diagnosed Multiple Myeloma Ineligible for Transplant
Data & Insights
Has run more than one trial at 29 of 128 partner sites.
Specializations
Breast Cancer and Gynecologic Oncology
Clinical activity includes hormone receptor-positive, HER2-negative and HER2-positive breast cancer, triple-negative breast cancer, and advanced ovarian, endometrial, cervical, and vulvar cancers, with interest in metastatic and recurrent solid tumors.
- Advanced breast cancer
- Metastatic ovarian cancer
- Recurrent endometrial cancer
- Cervical and vulvar squamous carcinoma
The therapeutic focus spans targeted and immunologic approaches in advanced malignancy, including treatment-resistant disease and biomarker-defined subgroups.
Hematologic Malignancies and Cell Therapy
Research involvement covers chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, and acute lymphoblastic leukemia.
- B-cell non-Hodgkin lymphoma
- Relapsed or refractory leukemia
- Myeloma
- CAR T-cell and other cellular therapies
There is particular emphasis on relapsed and refractory blood cancers, including post–cell therapy settings and advanced lymphoma subtypes.
Thoracic, Genitourinary, and Gastrointestinal Cancers
Clinical interests extend to non-small cell lung cancer, small cell lung cancer, urothelial carcinoma, renal cell carcinoma, prostate cancer, hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer, and pancreatic cancer.
- Lung cancer
- Urothelial and renal cancers
- Hepatobiliary malignancies
- Gastroesophageal and colorectal tumors
The therapeutic landscape includes advanced, metastatic, and biomarker-selected solid tumors across major organ systems.
Autoimmune, Inflammatory, and Immune-Mediated Diseases
Investigational activity includes systemic lupus erythematosus, lupus nephritis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease, ulcerative colitis, systemic sclerosis, idiopathic inflammatory myopathies, and IgA nephropathy.
- Autoimmune rheumatic disease
- Inflammatory bowel disease
- Immune-mediated kidney disease
- Myositis and vasculitic disorders
These areas reflect a strong therapeutic interest in immune modulation for chronic inflammatory and organ-specific autoimmune conditions.
Neurology, Cardiometabolic, and Ophthalmology
Additional activity spans Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, migraine, heart failure, atherosclerotic cardiovascular disease, type 2 diabetes, obesity, diabetic retinopathy, geographic atrophy, and glaucoma.
- Neurodegenerative disease
- Cardiovascular prevention
- Metabolic disease
- Retinal and optic nerve disorders
The therapeutic scope includes chronic neurologic disease, cardiometabolic risk reduction, and vision-threatening ocular conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.